Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure

被引:23
作者
Kuoppala, A
Shiota, N
Kokkonen, JO
Liesmaa, I
Kostner, K
Mäyränpää, M
Kovanen, PT
Lindstedt, KA
机构
[1] Wihuri Res Inst, FIN-00140 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Div Cardiol, Helsinki, Finland
[3] Allgemeines Krankenhaus Wien, Vienna, Austria
基金
芬兰科学院;
关键词
D O I
10.1016/S0735-1097(02)01928-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to study the expression of bradykinin type-2 receptors (BK-2Rs) in patients with heart failure (HF). BACKGROUND Recent work in experimental animals has suggested that bradykinin (BK) exerts cardioprotective effects through specific BK-2Rs. However, nothing is known about the regulation of BK-2R expression in the pathogenesis of human HF. METHODS Human heart tissue was obtained from excised hearts of patients undergoing cardiac transplantation (n = 13) and from normal hearts (n = 6) unsuitable for donation. The patients had HF due to idiopathic dilated cardiomyopathy (IDC) (n = 7) or coronary heart disease (CHD) (n = 6). Tissue samples from the left ventricles were analyzed by competitive reverse-transcriptase-polymerase chain reaction and Western blotting for the expression of BK-2R messenger ribonucleic acid (mRNA) and protein. RESULTS In both the IDC and CHD hearts, the level of BK-2R mRNA expression was found to be significantly lower (30% and 38% of control values, respectively) than that in normal hearts. Correspondingly, the BK-2R protein level was significantly reduced in both the IDC and CHD hearts (45% and 62% of control values, respectively) and apparently involved all myocardial cell types. The down-regulation of BK-2R expression in failing hearts did not correlate with decreased cellularity or with the expression pattern of other members of the G-protein-coupled receptor superfamily. However, BK-2R down-regulation in the failing hearts was associated with a decrease in endothelial nitric oxide synthase in both IDC (53% of control value) and CHD (43% of control value) hearts. CONCLUSIONS These results are the first to suggest that a loss of BK-2Rs is involved in the pathogenesis of human HF. (C) 2002 by the American College of Cardiology Foundation.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
[41]   Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure [J].
Kobayashi, Naohiko ;
Takeshima, Hiroshi ;
Koguchi, Wataru ;
Ishikawa, Mayuko ;
Sugiyama, Fumihiro ;
Ishimitsu, Toshihiko .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 :199P-199P
[42]   Cardioprotective Effects or Olmesartan on Apelin/APJ Pathway in Dahl Rats With End-stage Heart Failure [J].
Fukushima, Hiromichi ;
Kobayashi, Naohiko ;
Takeshima, Hiroshi ;
Koguchi, Wataru ;
Mamada, Yasuko ;
Hirata, Hisato ;
Machida, Yoshifumi ;
Suzuki, Noriko ;
Tabei, Kyoko ;
Ishimitsu, Toshihiko .
JOURNAL OF CARDIAC FAILURE, 2009, 15 (07) :S171-S171
[43]   MitraClip implantation in patients with end-stage systolic heart failure [J].
Fiorelli, F. ;
Giannini, C. ;
De Carlo, M. ;
Petronio, A. S. ;
Tamburino, C. ;
Capodanno, D. ;
Ettori, F. ;
Fiorina, C. ;
Bedogni, F. ;
Brambilla, N. .
EUROPEAN HEART JOURNAL, 2014, 35 :694-694
[44]   Differentiated approach to the treatment of patients with end-stage heart failure [J].
Shatova, O. Olesya ;
Kurlianskaya, A. ;
Rachok, L. ;
Ostrovsky, Y. .
EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 :378-379
[45]   The effect of heart transplantation on mortality in end-stage heart failure patients with UNOS status 2 [J].
Duygu, Hamza ;
Zoghi, Mehdi ;
Nalbantgil, Sanem ;
Engin, Cagatay ;
Yagdi, Tahir ;
Akilli, Azem ;
Akin, Mustafa ;
Ozbaran, Mustafa .
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2006, 34 (08) :479-483
[46]   Mechanisms contributing to the progression of left ventricular dysfunction to end-stage heart failure [J].
Böhm, M ;
Kilter, H ;
Kindermann, M .
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2003, 5 (0I) :14-21
[47]   Myocardial Regeneration in End-stage Heart Failure After Left Ventricular Unloading [J].
Pana, Tiberiu ;
Kepinski, Ingrid ;
Fairbourn, Adam ;
Afzal, Aneela ;
Savla, Jainy ;
Mammen, Pradeep P. ;
Drazner, Mark H. ;
Subramaniam, Rathan ;
Olson, Eric N. ;
Drakos, Stavros G. ;
Zaha, Vlad G. ;
Sadek, Hesham A. .
CIRCULATION, 2020, 142
[48]   Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ETA receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure [J].
Morawietz, H ;
Szibor, M ;
Goettsch, W ;
Bartling, B ;
Barton, M ;
Shaw, S ;
Koerfer, R ;
Zerkowski, HR ;
Holtz, J .
CIRCULATION, 2000, 102 (19) :188-193
[49]   Left ventricular assist devices as destination therapy for end-stage heart failure [J].
Stevenson L.W. .
Current Treatment Options in Cardiovascular Medicine, 2004, 6 (6) :471-479
[50]   Left ventricular assist devices as destination therapy for end-stage heart failure [J].
Yager, JEE ;
Felker, GM .
AMERICAN HEART JOURNAL, 2004, 148 (02) :252-253